Search

In Stock

Buy Verquvo (vericiguat) Online

DISEASE INDICATIONS: Risk of cardiovascular events

MANUFACTURER: Merck

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Pharmaceuticals and Medical Devices Agency (PMDA)

Verquvo (vericiguat) is a prescription medication used to treat chronic heart failure (CHF) with reduced ejection fraction (HFrEF). CHF is a condition in which the heart muscle is weakened and cannot pump blood as efficiently as it should. HFrEF is a type of CHF in which the left ventricle of the heart is not pumping blood as well as it should.

From $284.99

Clear
Compare

Verquvo (vericiguat) is a prescription medication used to treat chronic heart failure (CHF) with reduced ejection fraction (HFrEF). CHF is a condition in which the heart muscle is weakened and cannot pump blood as efficiently as it should. HFrEF is a type of CHF in which the left ventricle of the heart is not pumping blood as well as it should.

Description

Verquvo is a soluble guanylate cyclase (sGC) stimulator. sGC is an enzyme that produces cyclic guanosine monophosphate (cGMP), a molecule that helps to relax blood vessels and improve heart function. Verquvo works by directly stimulating sGC, which increases the production of cGMP. This can lead to improved heart function, reduced blood pressure, and decreased symptoms of CHF.

Uses

Verquvo is used to treat chronic heart failure (CHF) with reduced ejection fraction (HFrEF). HFrEF is a type of CHF in which the left ventricle of the heart is not pumping blood as well as it should. Verquvo can be used in combination with other CHF medications, such as beta-blockers, ACE inhibitors, and angiotensin receptor blockers (ARBs).

How to use

Verquvo is taken orally once daily with food. The recommended starting dose is 2.5 mg. The dose can be doubled every 2 weeks until the target maintenance dose of 10 mg is reached. The dose may need to be adjusted based on the patient’s tolerability.

Dosage

The recommended starting dose of Verquvo is 2.5 mg orally once daily with food. The dose can be doubled every 2 weeks until the target maintenance dose of 10 mg is reached. The dose may need to be adjusted based on the patient’s tolerability.

Mechanism of action

Verquvo works by directly stimulating soluble guanylate cyclase (sGC), an enzyme that produces cyclic guanosine monophosphate (cGMP). cGMP is a molecule that helps to relax blood vessels and improve heart function. By increasing the production of cGMP, Verquvo can improve heart function, reduce blood pressure, and decrease symptoms of CHF.

Storage conditions

Verquvo should be stored at room temperature (68°F to 77°F) away from light and moisture.

Precautions

Verquvo can cause hypotension (low blood pressure). Patients should be monitored for signs and symptoms of hypotension, such as dizziness, lightheadedness, and fainting. If hypotension occurs, the dose of Verquvo may need to be reduced or discontinued.

Verquvo can also cause anemia. Patients should be monitored for signs and symptoms of anemia, such as fatigue, shortness of breath, and pale skin. If anemia occurs, the dose of Verquvo may need to be reduced or discontinued.

Interactions

Verquvo can interact with other medications, such as nitrates, alpha-blockers, and certain antihypertensives. Patients should tell their doctor about all of the medications they are taking before starting Verquvo.

Contraindications

Verquvo is contraindicated in patients with the following conditions:

  • Hypotension (low blood pressure) with systolic blood pressure less than 90 mmHg
  • Severe aortic stenosis
  • Severe pulmonary hypertension
  • Pregnancy
  • Lactation

Side effects

The most common side effects of Verquvo are:

  • Hypotension (low blood pressure)
  • Anemia
  • Headache
  • Dizziness
  • Nausea
  • Diarrhea
  • Edema (swelling)

Overdose

There is no known specific antidote for Verquvo overdose. Treatment should be supportive and include monitoring of vital signs, fluid replacement, and vasopressor therapy if needed.

If you have any questions or concerns about Verquvo, please talk to your doctor.

Package

14 tablets of 2.5 mg, 14 tablets of 5 mg, 30 count bottle of 2.5 mg tablets, 30 count bottle of 5 mg tablets, 30 count bottle of 10 mg tablets, 90 count bottle of 10 mg tablets, 98 tablets x 5 mg

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Nexletol (bempedoic acid) Online

$426.42
(0 Reviews)
DISEASE INDICATIONS: Hypercholesterolemia MANUFACTURER: Esperion Therapeutics USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Nexletol is a prescription medication used to lower cholesterol levels in patients with hypercholesterolemia.

Buy Orladeyo (berotralstat) Online

$17,967.38
(0 Reviews)
MANUFACTURER: BioCryst Pharmaceuticals USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Pharmaceuticals and Medical Devices Agency (PMDA) Orladeyo is a prescription medication used to prevent attacks of hereditary angioedema in adults and children by reducing the frequency of attacks. It is a subcutaneous injection that works by inhibiting kallikrein, an enzyme involved in the production of bradykinin.

Buy Verquvo (vericiguat) Online

From $284.99
(0 Reviews)
DISEASE INDICATIONS: Risk of cardiovascular events MANUFACTURER: Merck USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Pharmaceuticals and Medical Devices Agency (PMDA) Verquvo (vericiguat) is a prescription medication used to treat chronic heart failure (CHF) with reduced ejection fraction (HFrEF). CHF is a condition in which the heart muscle is weakened and cannot pump blood as efficiently as it should. HFrEF is a type of CHF in which the left ventricle of the heart is not pumping blood as well as it should.

Buy Repatha SureClick (evolocumab) Online

$629.98
(0 Reviews)
DISEASE INDICATIONS: Risk of cardiovascular events, Hypercholesterolemia MANUFACTURER: Amgen Inc. USAGE: Subcutaneous MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Pharmaceuticals and Medical Devices Agency (PMDA) Repatha is a subcutaneous injection used to lower LDL cholesterol levels in adults with primary hyperlipidemia or mixed dyslipidemia and in individuals with clinical atherosclerotic cardiovascular disease who require additional LDL cholesterol reduction. It binds to and inhibits PCSK9, promoting the clearance of LDL cholesterol from the bloodstream.

Buy Vascepa (icosapent ethyl) Online

From $530.34
(0 Reviews)
DISEASE INDICATIONS: Risk of cardiovascular events, Hypertriglyceridemia MANUFACTURER: Amarin Pharma Inc USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Health Canada Vascepa (icosapent ethyl) is a medication used to reduce the risk of cardiovascular events in adults with established cardiovascular disease or elevated triglyceride levels.

Buy Entresto (sacubitril/valsartan) Online

From $148.92
(0 Reviews)
DISEASE INDICATIONS: Risk of cardiovascular events MANUFACTURER: Novartis USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Entresto is a combination medication used to treat chronic heart failure in adults, containing sacubitril and valsartan.

Back to Top
Product has been added to your cart